XBiotech Inc
Suletud
2.31
Ülevaade
Aktsiahinna muutus
24h
Min
2.26
Max
2.34
Sissetulek | 21M -5.5M |
|---|---|
Aktsiakasum | -0.181 |
Töötajad | 87 |
EBITDA | 24M -5.1M |
Järgmine tulemuste avaldamine | 11. aug 2026 |
|---|
Turukapital | -4.9M 70M |
|---|---|
Eelmine avamishind | 2.31 |
Eelmine sulgemishind | 2.31 |
XBiotech Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.